Login
$GPCR
$18.56 -$0.01 (0.05%) After hours

$GPCR SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028

05 Nov 2026 SCHEDULE 13G/A
22 Sep 2026 Form 4: Coll Crespo Blas, CHIEF MEDICAL OFFICER

Gave up 10,626 shares to cover exercise price or tax ($124K) · Disposed of 12,024 shares (Derivative Conversion) · Acquired 4,008 American Depositary Shares (Derivative Conversion) · 1 more

21 Sep 2026 144
08 Sep 2026 8-K: Regulation FD Disclosure; Other Events

2 This presentation contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995. All statements other than statements of historical fact are statemen...

02 Sep 2026 Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER

Received 17,817 shares by exercise or conversion ($6.06K) · Disposed of 17,817 shares (Derivative Conversion) · Acquired 5,939 American Depositary Shares (Derivative Conversion) · 1 more

19 Aug 2026 Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER

Received 11,817 shares by exercise or conversion ($4.02K) · Disposed of 11,817 shares (Derivative Conversion) · Acquired 3,939 American Depositary Shares (Derivative Conversion) · 1 more

07 Aug 2026 Form 4: Berrios John Joseph, Chief Commercial Officer

Received 140,766 shares as a grant or award · Granted 174,612 Share option (right to buy)

07 Aug 2026 Form 3: Berrios John Joseph, Chief Commercial Officer

No securities owned

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management

06 Aug 2026 SCHEDULE 13G/A
05 Aug 2026 Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER

Received 11,817 shares by exercise or conversion ($4.02K) · Disposed of 11,817 shares (Derivative Conversion) · Acquired 3,939 American Depositary Shares (Derivative Conversion) · 1 more

24 Jul 2026 Form 4: Fmr Llc, 10% owner

Disposed of 17,452 American Depositary Shares (Open Market Sale) ($874K)

15 Jul 2026 Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER

Received 23,634 shares by exercise or conversion ($8.04K) · Disposed of 23,634 shares (Derivative Conversion) · Acquired 7,878 American Depositary Shares (Derivative Conversion) · 1 more

29 Jun 2026 Form 4: Lin Xichen, CHIEF SCIENTIFIC OFFICER

Received 23,634 shares by exercise or conversion ($8.04K) · Disposed of 23,634 shares (Derivative Conversion) · Acquired 7,878 American Depositary Shares (Derivative Conversion) · 1 more

25 Jun 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support